The hemophilia community is telling FDA that it wants access to post-market safety surveillance data on factor replacement therapies in order to better understand the development of inhibitors, or neutralizing antibodies, that many patients experience.
Patients aired their concerns at a Sept. 22 patient-focused drug development meeting organized by the agency’s Center for Biologics Evaluation and Research to receive input on a range of issues...